Gaunt DM

References (3)

Title : Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease - Neumann_2021_BMC.Neurol_21_422
Author(s) : Neumann S , Taylor J , Bamford A , Metcalfe C , Gaunt DM , Whone A , Steeds D , Emmett SR , Hollingworth W , Ben-Shlomo Y , Henderson EJ
Ref : BMC Neurol , 21 :422 , 2021
Abstract : Neumann_2021_BMC.Neurol_21_422
ESTHER : Neumann_2021_BMC.Neurol_21_422
PubMedSearch : Neumann_2021_BMC.Neurol_21_422
PubMedID: 34715821

Title : The minimum clinically important difference (MCID) for a falls intervention in Parkinson's: A delphi study - Henderson_2019_Parkinsonism.Relat.Disord_61_106
Author(s) : Henderson EJ , Morgan GS , Amin J , Gaunt DM , Ben-Shlomo Y
Ref : Parkinsonism Relat Disord , 61 :106 , 2019
Abstract : Henderson_2019_Parkinsonism.Relat.Disord_61_106
ESTHER : Henderson_2019_Parkinsonism.Relat.Disord_61_106
PubMedSearch : Henderson_2019_Parkinsonism.Relat.Disord_61_106
PubMedID: 30455158

Title : Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial - Henderson_2016_Lancet.Neurol_15_249
Author(s) : Henderson EJ , Lord SR , Brodie MA , Gaunt DM , Lawrence AD , Close JC , Whone AL , Ben-Shlomo Y
Ref : Lancet Neurol , 15 :249 , 2016
Abstract : Henderson_2016_Lancet.Neurol_15_249
ESTHER : Henderson_2016_Lancet.Neurol_15_249
PubMedSearch : Henderson_2016_Lancet.Neurol_15_249
PubMedID: 26795874